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Background: Children are recognized as “therapeutic orphan” in many parts of the world,
one expression of this is the lack of adequate pediatric labeling information. Some research
studies have been done to investigate the pediatric labeling condition in the U.S. and other
countries, but no national studies had been carried out in China.This survey was conducted
aiming to inquire the current situation of pediatric labeling in China.
Methods: We investigated 6020 child-applied medicines from 15 representative Chi-
nese hospitals, and analyzed the information according to the dosage forms, therapeutic
category, and label information integrity.
Results: Among all these medicines, only 238 (3.95%) are pediatric products, the rest
are adult formulations with an extended use in children. The major pediatric formulations
were injection (45.95%), tablet (23.69%), and capsule (4.93%), respectively. Alimentary
tract/metabolism medicine (24.70%) and infections medicines (20.60%) had the most
species. In prescription drugs, only 210 of 5187 (4%) medicines had adequate pediatric
labeling information. The main cause of this deficiency was lack of evidence derived from
pediatric clinical trials.
Conclusion: The dilemma of “therapeutic orphan” requires significant attention. Inade-
quate labeling information and lack of pediatric clinical trials were two prominent issues
in China. It calls for more efforts from pharmaceutical industries, regulatory agencies, and
legislature in China to collaborate and find solution to improve the situation.
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INTRODUCTION
Forty years ago,after the tragedy of fetal malformation from mater-
nal ingestion of thalidomide, Dr. Harry Shirkey first pointed out
the dilemma of pediatric therapy and raised the concept of “ther-
apeutic orphan” (1, 2). That started the first step of the long
journey of labeling all the therapeutic drugs for children. A com-
plete label should include important information on indications
and usage, clinical pharmacology, contraindications, precautions,
adverse effects, dosage, and administration. Labeling of a drug
indicates that there is adequate evidence from clinical trials to
ensure the drug has reached an applied moral, ethical, and med-
ical standard, so that it is safe and effective to use toward a certain
population (3, 4). But pediatric labels often fail to reach that
standard.
In 1975, Wilson investigated the US Physicians’ Desk Reference
(PDR) and discovered only 22% of drug labeling had adequate
pediatric information (5). In 2009, the proportion upgrades to
41% (6). China is the home to nearly 300 million children. The
phenomenon of lack of labeling information in children is also
a critical issue in China, yet very few studies have been carried
out nationwide (7). This study was undertaken aiming to inves-
tigate the current pediatric medicine labeling situation with the
intension that it may help to promote the collaborative efforts
among pharmaceutical industry, the regulatory agencies of the
country, and legislature professionals to provide child-friendly
formulations and adequately label the medicines for infants and
children.
MATERIALS AND METHODS
This study investigated the pediatric labeling in 15 top-ranked
Chinese medical facilities by questionnaire, including the basic
condition of pediatric drugs in each facility, their dosage forms,
therapeutic category, and label information integrity.
BASIC CONDITION
From July 2011 to December 2011, 15 Chinese medical facili-
ties participated in the survey; they are either children’s hospitals
or general ones that are top ranked in China and have excellent
pediatric departments. Demarcated from national administrative
zones, six were from Eastern China, including Children’s Hos-
pital of Fudan University, Shanghai Xinhua Hospital, Nanjing
Children’s Hospital, Zhejiang University affiliated Children’s Hos-
pital, Anhui Provincial Children’s Hospital, Children’s Hospital of
Harbin City; three from Central China, Beijing Children’s Hos-
pital, Peking University Third Hospital, Children’s Hospital of
Shanxi Province; five from the west, Chongqing Medical University
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affiliated Children’s Hospital, West China Women’s and Children’s
Hospital, Children’s Hospital of Xian City, Children’s Hospital
of Guiyang, Qinghai Women and Children Hospital, Guangxi
Maternal and Children Health Hospital. These hospitals are rep-
resentative in both the regional coverage and health care quality
level. The results are reliable.
We investigated the labeling information for drugs used in
children among the aforesaid hospitals. Drugs were divided into
prescription and over-the-counter (OTC) products. Each category
was then split into child-specific and child-used. Child-specific
means medicines or formulations designed and produced to use
exclusively in children. For example, poractant alfa (Curosurf) is
the medicine used only in premature infants to treat respiratory
distress syndrome. Ibuprofen suspension drops (Motrin) is the
special formulation designed for children. Child-used definited
as medicines or formulations designed and produced mainly for
adults, but also have an extended use in children. For example,
meropenem is used for both adults and children. The same com-
pound or composition with different formulations, specifications,
and pharmaceutical companies was double-checked to identify
discrepancies on their indications and labeling integrity.
DOSAGE FORMS
The dosage forms and the corresponding data and percentage were
listed. The forms were classified as parenteral administration, oral
administration, cutaneous administration, preparation for eye,
ear, and nose, orally inhaled (pulmonary) medicine, and rectal
administration.
THERAPEUTIC CATEGORY
The therapeutic category and percentage of pediatric prescription
and non-prescription medicines were investigated and analyzed.
The anatomical therapeutic chemical classification system (ATC)
was used.
LABEL INFORMATION INTEGRITY
The pediatric label information integrity of prescription medi-
cines and non-prescription ones were shown in the following.
RESULTS
FORMULATIONS INTENDED FOR CHILD-SPECIFIC VERSUS CHILD-USED
In all the investigated hospitals, there was a total of 6020 products
used for children, 5187 prescription and 833 non-prescription
drugs; while the child-specific were 124 (2.39%) among pre-
scription drugs and 114 (13.69%) among non-prescription ones,
respectively (Table 1). The child-specific proportion is low, and
the phenomenon of adult products off-label use in pediatric
population is serious in China, especially in prescription drugs.
DOSAGE FORMS
In the survey, there were 32 dosage forms for child-specific and
among them, injection (53.48%), tablet (21.62%), and capsule
(4.81%) had the most species of dosage forms for prescription
drugs; while tablet (36.75%), oral solution (9.31%), and ointment
(8.35%) were common dosage forms for OTC drugs. The child-
specific drugs covered 13 different dosage forms in prescription
medicines and 11 forms in OTC ones, which both of them were
less than half of child-used ones (Table 2).
Table 1 | Pediatric medication usage in selected hospitals.
Hospital Prescription drugs OTC drugs
Child-specific Child-used Child-specific Child-used
CHF 9 410 13 77
SXH 6 151 4 18
NCH 14 467 10 62
ZCH 13 467 11 61
ACH 7 334 7 49
CHH 10 266 9 30
BCH 10 508 13 54
PTH 6 482 13 117
CHS 12 340 3 44
CCH 9 371 7 49
WWC 7 481 7 68
CHX 10 288 7 34
CHG 6 139 5 18
QWC 5 253 5 19
GMC 0 106 0 19
Total 124 5063 114 719
CHF, Children’s hospital of Fudan University; SXH, Shanghai Xinhua hospital; NCH,
Nanjing children’s hospital; ZCH, Zhejiang University affiliated children’s hospital;
ACH, Anhui provincial children’s hospital; CHH, the children’s hospital of Harbin
city; BCH, Beijing children’s hospital; PTH, Peking University third hospital; CHS,
the children’s hospital of Shanxi province; CCH, Chongqing Medical University
affiliated children’s hospital; WWC, West China women’s and children’s hospital;
CHX, the children’s hospital of Xian city; CHG, the children’s hospital of Guiyang;
QWC, Qinghai women and children hospital; GMC, Guangxi maternal and children
health hospital.
Noticeably, injection is the largest species in Chinese pediatric
prescription drugs, but only 1 out of 60 (45/2766) injections were
developed for pediatric use. The well majority of the injections,
which children have access to were intended for adults, and most
of them had no evidence from clinical trials to ensure the effi-
cacy in pediatric population. Meanwhile, this may also raise the
risk of therapeutic safety or even cause therapeutic disasters from
either the pharmaceutical active component itself or the excipi-
ents. Benzyl alcohol, a bacteriostatic agent, is a common excipient
in many intravenous products for adults, including cotrimoxa-
zole, digoxin, phenobarbital, etc. It is likely to cause kernicterus,
intra-ventricular, or “grasping syndrome” in pre-term infants due
to their immature liver detoxification function (8, 9). In addition,
it is worth questioning if pediatric patients really need so many
injections.
Tablet and capsule were another two formulations and fre-
quently chosen in children. When drugs for adults were extempo-
rized into pediatric use, especially in infants and young children,
the products need sub-divided, crushing, or sometime even dis-
persing, since young infants need less dosage or some children are
unable to swallow the whole solid unit dosage forms. That unit
tablet and capsule would result in a decreased dosing flexibility as
compared to oral liquid preparations and oral flexible solid dosage
forms (9). So more pediatric use formulations adapt to child-size
and child administration route are greatly encouraged.
Frontiers in Pediatrics | Obstetric and Pediatric Pharmacology March 2014 | Volume 2 | Article 17 | 2
Li et al. Pediatric labeling in China
Table 2 | Dosage forms of pediatric medicines.
Dosage form Prescription drugs OTC drugs Total
Child-specific (%) Child-used (%) Child-specific (%) Child-used (%)
PARENTERAL ADMINISTRATION
Injection 45 (1.63) 2721 (98.37) 0 (0.00) 0 (0.00) 2766
ORAL ADMINISTRATION
Tablet 8 (0.56) 1110 (77.84) 19 (1.33) 289 (20.27) 1426
Capsule 9 (3.03) 240 (80.81) 1 (0.34) 47 (15.82) 297
Oral solution 19 (6.93) 150 (54.74) 39 (14.23) 66 (24.09) 274
Granule 25 (13.66) 99 (54.10) 16 (8.74) 43 (23.50) 183
Suspension 1 (0.70) 107 (75.35) 17 (11.97) 17 (11.97) 142
Syrup 1 (1.89) 22 (41.51) 6 (11.32) 24 (45.28) 53
Gelata 0 (0.00) 36 (78.26) 0 (0.00) 10 (21.74) 46
Dripping pilla 0 (0.00) 6 (27.27) 3 (13.64) 13 (59.09) 22
Emulsion 3 (16.67) 15 (83.33) 0 (0.00) 0 (0.00) 18
Elixir 6 (66.67) 3 (33.33) 0 (0.00) 0 (0.00) 9
Orally freeze-dried powder 0 (0.00) 8 (100.00) 0 (0.00) 0 (0.00) 8
Othersb 1 (14.29) 2 (28.57) 1 (14.29) 3 (42.86) 7
CUTANEOUS ADMINISTRATION
Ointment 0 (0.00) 95 (57.58) 0 (0.00) 70 (42.42) 165
Pulvis 2 (2.17) 47 (51.09) 7 (7.61) 36 (39.13) 92
Lotion 0 (0.00) 4 (14.81) 0 (0.00) 23 (85.19) 27
Liniment 0 (0.00) 11 (73.33) 0 (0.00) 4 (26.67) 15
Patch 0 (0.00) 8 (57.14) 0 (0.00) 6 (42.86) 14
Gargle 0 (0.00) 2 (28.57) 0 (0.00) 5 (71.43) 7
PREPARATION FOR EYE, EAR, AND NOSE
Orphanology solution 0 (0.00) 145 (90.06) 0 (0.00) 16 (9.94) 161
Ophthalmology ointment 0 (0.00) 13 (61.90) 0 (0.00) 8 (38.10) 21
Ear drop 0 (0.00) 4 (80.00) 0 (0.00) 1 (20.00) 5
Nasal drop 0 (0.00) 2 (66.67) 0 (0.00) 1 (33.33) 3
INHALATION (PULMONARY) MEDICINE
Aerosol(MDI) 0 (0.00) 132 (98.51) 0 (0.00) 2 (1.49) 134
Nasal spray 0 (0.00) 48 (80.00) 0 (0.00) 12 (20.00) 60
RECTAL ADMINISTRATION
Suppository 4 (11.43) 13 (37.14) 4 (11.43) 14 (40.00) 35
Enema 0 (0.00) 5 (25.00) 0 (0.00) 15 (75.00) 20
aDripping pill: softgel capsule containing medication that can be squizzed out for oral administration.
bOthers: including tincture, pills, and sugar pills.
THERAPEUTIC CATEGORY
According to WHO ATC-coding, alimentary tract and metabo-
lism medicine (24.70%), Infections and infestations medicines
(20.60%), and Brain and nervous system medicines (10.83%)
were the main therapeutic category of Chinese pediatric drugs
(Table 3).
Infections and infestations medicines had the most species in
pediatric prescription drugs. But, there is only one type of pedi-
atric specialty formulation. As a result, the adult antibiotics and
adults formulations are commonly used in children that may cause
potential risk especially in neonates and small infants. Besides
antibacterial, nutrition and NSAIDs are the most widely used
drugs in pediatric population, which showed the consistency with
several European studies (10, 11).
LABEL INFORMATION INTEGRITY
The integrity of prescription and non-prescription medicines was
shown in the following tables (Tables 4 and 5). We analyzed
the items in the drug instructions, and compared condition of
child-specific and child-used ones.
There were fewer items in drug instructions for pediatric OTC
medicines.
Among all the drug instruction items, the integrity of “indi-
cation” and “dosage” was much higher than the rest. That may
be understood as drugs available must first focus on the essential
need for pediatric use. Given that “clinical trials” had got the least
description in the prescription medicine and was omitted in most
OTC package insert, drug selection, and dose titration for children
have to be based on clinical researches issued on medical literatures
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Table 3 |Therapeutic category of pediatric medicines.
Therapeutic category Prescription drugs Non-prescription drugs Total
Child-specific (%) Child-used (%) Child-specific (%) Child-used (%)
A 66 (4.44) 1044 (70.21) 69 (4.64) 308 (20.71) 1487
J 5 (0.40) 1215 (97.99) 0 (0.00) 20 (1.61) 1240
N 2 (0.31) 636 (97.55) 0 (0.00) 14 (2.14) 652
R 25 (4.92) 360 (70.87) 2 (0.39) 121 (23.82) 508
C 6 (1.45) 407 (98.55) 0 (0.00) 0 (0.00) 413
L 3 (0.73) 408 (99.27) 0 (0.00) 0 (0.00) 411
B 1 (0.34) 259 (89.31) 0 (0.00) 30 (10.34) 290
S 5 (1.92) 219 (83.91) 0 (0.00) 37 (14.17) 261
M 10 (4.95) 85 (42.08) 41 (20.30) 66 (32.67) 202
D 0 (0.00) 111 (56.63) 0 (0.00) 85 (43.37) 196
G 0 (0.00) 85 (100.00) 0 (0.00) 0 (0.00) 85
V 1 (0.36) 207 (75.27) 0 (0.00) 67 (24.37) 275
A: alimentary tract and metabolism; J: infections and infestations; N: brain and nervous system; R: respiratory system; C: cardiovascular system; L: malignant and
immune disease; B: blood and blood forming organs; S: sensory organs; M: muscles, bones and joints; D: skin; G: genitourinary system;V: others, including Diagnostic
agents, Disinfectants and antiseptics, Radioactive drugs.
Table 4 | Pediatric label information integrity of prescription medicine.
Drug
information
Child-specific
(number)
Child-
specific (%)
Child-used
(number)
Child-
used (%)
Dosage 120 96.77 2562 50.60
ADR 86 69.35 603 11.91
Contraindications 71 57.26 371 7.33
Special notes 90 72.58 885 17.48
Indications 94 75.81 4089 80.76
Drug interactions 64 51.61 132 2.61
Pharmacokinetics 56 45.16 628 12.40
Drug overdose 57 45.97 301 5.95
Clinical trials 12 9.68 198 3.91
PD/toxicology 76 61.29 225 4.44
ADR, adverse reaction; PD, pharmacodynamics.
Table 5 | Pediatric label information integrity of non-prescription
medicine.
Drug information Child-specific
(number)
Child-
specific (%)
Child-used
(number)
Child-
used (%)
Dosage 110 96.49 334 46.45
ADR 60 52.63 30 4.17
Contraindications 50 43.86 43 5.98
Special notes 99 86.84 604 84.01
Drug interactions 51 44.74 16 2.23
ADR, adverse reaction.
or extrapolation of adult labeling information. That would likely
cause ineffective therapy or toxic results in pediatric patients.
In general, child-specific medications showed higher integrity
on label information than child-used, for both prescription and
non-prescription medicines. As such, if it is optional, child-specific
medicines are strongly recommended. They not only possess bet-
ter labeling integrity, but also more considerable for child use, for
example masking the odd smell, making medicines child-size.
DISCUSSIONS
THERAPEUTIC ORPHAN IN CHINA
Although the concept of “therapeutic orphan” was raised more
than 40 years ago, the therapeutic dilemma had not been signifi-
cantly changed. The phenomenon of extrapolating dosing infor-
mation from adults to children is still in many areas worldwide. Yet,
we clearly recognized that the effects of many drugs on children
may vary dramatically from what was seen in adults. The main
reason is significant physical and maturation changes that occur
from newborn to adolescence. Ontogeny of drug absorption, dis-
tribution, metabolism, and elimination makes children different
from adults (12, 13).
In the United States, there were several milestones in the pedi-
atric labeling process. As early as the late 1930s, after 107 children
death cause by diethylene glycol administration, the food, drug,
and cosmetic act (FDCA) was amended to include not only a
requirement to provide adequate directions for use and disclosure
of composition and method of preparation of medicines, but also
evidence of products’ safety (14, 15). Another well-known tragedy
worldwide was induced by thalidomide, which entered the mar-
ket in 1957 as a sedation to alleviate nausea and vomit during
pregnancy, unfortunately, the gestation mother were “vulnerable
populations” to this new drug, and more than 10,000 cases of birth
defect over 30 countries were caused. As a response, the Kefauver–
Harris Drug Amendments was made in 1962. The thalidomide
issue also reminds people that the safety and efficacy in ordinary
adults cannot be applied to vulnerable populations (16–18). So
in 1979, the Food and Drug Administration (FDA) required that
recommendations for pediatric use should be based on evidences
from adequate and well controlled studies in pediatric population,
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unless they were waived. This revision was intended to encourage
pediatric clinical trials, but turned out to be in opposite effect.
The 1994 Final Rule for pediatric labeling continued to clarify the
FDA position on various procedures that can get pediatric label-
ing, and compromise that in certain cases, drugs may be labeled for
pediatric use if there were adequate evidence from well controlled
studies in adults, with pharmacokinetic and safety data in pediatric
population. What’s more, from 2002 to 2003, the Best Pharmaceu-
ticals for Children Act, in exchange for study the drug in children,
the drug maker gets more 6 months of selling their products with-
out competition, and the Pediatric Research Equity Act gives FDA
the right to ask drug companies to study the effectiveness of new
drugs in children (19).
The teratogenic effect of thalidomide also strengthened the
awareness of the European authorities. As a result, Directive
65/65/EEC1 was installed. EU law is having a considerable effect
on drug development in children. The new legislation [European
Regulation (EC) No. 1901/2006], named the “Pediatric Regula-
tion” governing the development and authorization for use of
medicines in the child population, entered into force on 26 Janu-
ary 2007 (20). The Pediatric Regulation brings in many new tasks
and responsibilities for the European Medicines Agency (EMA).
One of the most important is the creation and operation of a
Paediatric Committee (PDCO) within the EMA (21). The Com-
mittee includes pediatric experts from all over the EU. The main
responsibility of the PDCO is to assess the content of pediatric
investigation plans (PIPs) that are proposed by industry, and to
provide opinions on them in accordance with the Pediatric Reg-
ulation. For new medicinal products of therapeutic interest for
children, the EU requires early submission of a PIP for approval
by the PDCO. PIP submissions are expected to be filed at the
time of completion of adult clinical pharmacology and pharma-
cokinetic studies (phase I), i.e., early in product development,
in order to facilitate dialog and avoid any delay at the time of
marketing authorization application. The objective is to ensure
that medicines intended for eventual use in children are evaluated
and authorized appropriately in all pediatric age groups, including
neonates.
In China, the lack of evidence supporting drug use in children is
also causing many serious problems. Yang investigated the special
education schools in China, and found nearly 70% of the defor-
mity children were caused by irrational use of medicines (22).
Nevertheless, there are still very few regulations and policy leg-
islated to improve the safety and efficacy use of medicines and
clinical trials for Chinese children. In 2003, the State Food and
Drug Administration (SFDA) published Good Clinical Practice,
and regulated if a child was joining in the clinical trial, informed
consent must be signed by their guardian (23). In 2004, SFDA pub-
lished Guidelines of Vaccine Clinical Trials, mentioned that when
clinical trials is conducted in children, there must be adequate
consideration on ethical issues (24). But the good intention to
protect children may actually have opposite effect, since conduct-
ing clinical trials in children means extra cost and risk confronted
by pharmaceutical companies.
The result of our study shows that only 210 out of 5187 child-
applied prescriptive medicines had information derived from clin-
ical trials, even some of them only possess evidence in adult clinical
trials and pharmacokinetic and safety data in children. While in
non-prescription medicines, the data in pediatric clinical trials is
nearly blank.
THE ISSUE OF CHINA’S PEDIATRIC LABELING INTEGRITY
From the study methods established by Wilson (3, 5) and his fol-
lowers (6), labeling was categorized as adequate if it stated that
the drug was approved for pediatric use, had been studied, and
had safety, efficacy, dosing information for all appropriate pedi-
atric populations, which we adapted as indication, clinical trials,
adverse reaction, and dosages in different groups in our study.
In Wilson’s study, there was only 22% of all prescription elec-
tronic Physician’s Desk Reference (ePDR) had pediatric informa-
tion in 1975, the ratio raised to 41% in 1999 and 46% in 2009.
In 2009, 50% of prescription child-applied medicines were ade-
quately labeled for pediatric use. Topicals, nasal sprays, and most
OTC products were excluded per the methods of Wilson.
In our study, we evaluated 5187 child-applied prescription
medicines, among which only 4% products had adequate pedi-
atric information, which is far behind the ratio of U.S. The main
reason is that only a few drugs had been carried out clinical trials
in pediatric population. If the medicines were re-evaluated when
“clinical trial” item was removed, the adequate label rate was 13%.
The label integrity standard between Chinese prescription
and OCTs are quite different. In prescription drugs, dosage,
adverse reaction, contraindication, special notes, indication, drug
interaction, pharmacokinetics, drug overdose, clinical trials, and
PD/toxicology are included, while in OTCs, only dosage, adverse
reaction, contraindication, special notes, and drug interaction are
involved. Within the categories, different medicines shared differ-
ent integrity. In general, the essential medicines from international
drug manufactories usually have better integrity than domes-
tic generic drugs. To unify the level of pediatric label integrity,
national legislation must intervene.
Many of unlicensed and off-label drugs are not available in
pediatric formulation and had to be modified by the pharmacy
department to make them suitable for administration to chil-
dren. Stability data are rarely available for such products, which
are rendered unlicensed by this modification.
Another issue is the generic drugs. Generic drugs are very
common in China, different regions may have different medical
enterprises producing the same drug, but the levels vary greatly,
and the integrity of labels is also different. The hospitals in differ-
ent regions prefer, using their local products besides the imported
ones, since they are easier to get. Yet this may cause not only
the label integrity problems, but also serious health risks for the
receivers (patients).
DEVELOPING PEDIATRIC SPECIALTY DRUG PRODUCTS IN CHINA TO
SATISFY THE UNMET MEDICAL NEED
In December 2007, WHO launched an initiative for “Make Medi-
cine Children Size” in order to encourage and accelerate research,
development, and test of appropriate dosage forms for pediatric
population. This action highlighted the urgent need for acces-
sibility and availability of pediatric formulations. Challenges for
appropriate pediatric dosage forms are not only derived from the
unique status of physiological conditions and disease states, but
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also the heterogeneous nature of pediatric patients. For example,
children groups are sub-divided as (1) new born (0–27 days);
(2) infant (28 days–2 years); (3) toddlers (2–5 years); (4) children
(6–11 years); adolescents (>12 years old). Each age group has dif-
ferent preference to the dosage forms and therefore, should drive
the decision of pediatric dosage form selections. For example,
injectable medication is preferable for the new born. Syrup, oral
solution or suspensions are mostly appropriate for the infants and
toddlers. Studies conducted in Norway showed that more than
50% of children prefer liquids/suspensions even for 12 years old.
Younger children, especially at disease stage, strongly prefer liq-
uids/suspensions (25, 26). Age appropriate specialty formulations
in pediatric population should consider the following factors: (1)
Safety: excipients, drug degradation products, potential interac-
tions between excipients and drug substance are proven safe and
acceptable to the targeted population group; (2) Easy adminis-
tration and dosing accuracy: this is particularly important for
medications that will be given based on body weight or surface
areas. The dosage form should allow flexibility in accurately sub-
dividing the dose, such as measured by volume for oral solution
or suspensions; (3) palatable: children are very sensitive to the
taste. Many medications have un-pleasant taste, and thus should
be properly taste-masked in pediatric dosage forms to ensure com-
pliance and adherence. Adherence to the full strength dose and
dosing regimen are the most important measures to achieve ther-
apeutic efficacy as well as to reduce the side effect; (4) appropriate
dosing device: this is to ensure accurate delivery of appropriate
doses; but unfortunately is a largely ignored area.
In summary, accessibility of appropriate pediatric drug prod-
ucts to pediatrician, hospitals is the critical element in “providing
right medicine to children.” Appropriate pediatric dosage forms
will provide a powerful tool for clinicians to conduct pediatric
clinical trials that lead to better pediatric labeling; and most
importantly allow accurate delivery of medications to children.
CONCLUSION
Children, the “therapeutic orphan,” seem to be more marooned
in China. Despite the inadequate labeling information and fewer
clinical trials, there are even more problems for this group in China,
such as imbalanced ability to access the essential or better medi-
cines in different regions, the duplication of generic drug at a low
level, and the parents’ blindly trusting in the use of injections. In
the developed countries, people began to realize the special char-
acteristics and need of children more than 50 years ago, a series
of law and regulations had been formulated to increase pediatric
labeling situation. But in China, there is no national list of pedi-
atric essential medicines, and there is very little pharmaceutical
legislation to protect children from harms of irrational drug use
from the national level.
In the twenty-first century, China is developing rapidly in many
aspects, but as far as we are really willing to get some benefit to our
children, and make pediatric drug use safer and more effective,
we need to work together since China is the home of nearly 300
million children. The pharmaceutical industry need to sponsor
the necessary studies, the SFDA enforce its regulations, the legis-
lature to mandate all child-applied medicines should be evaluated
appropriately, and the public be adequately educated, if all of these
may be transformed, the therapeutic orphan will disappear into
an awkward moment of medical history.
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